STAAR Surgical Company · NASDAQ:STAA
STAAR Surgical — Investor Presentation (June 2022)
21 slides from STAAR Surgical's investor presentation, June 2022
Slide 1: STAAR Surgical Investor Presentation
Envision a Life Without Hesitation STAAR Surgical Investor Presentation NASDAQ: STAA | June 2022
Slide 2: Forward Looking Statements
Forward Looking Statements All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2022 or prospects for achieving such
Slide 3: Who Is STAAR Surgical?
Who Is STAAR Surgical? 01 Exclusive manufacturer of proprietary EVO Visian® Family of Implantable Collamer® Lenses (EVO ICL) used worldwide to correct refractive error 02 Executing against a rapidly expanding global Total Addressable Market (TAM) of millions of eyes Achieving industry-leading growth
Slide 4: Refractive Error is a Global Epidemic
Refractive Error is a Global Epidemic Myopia • More near work, less time outdoors, cell phones, screen time, gaming, Distance Vision education/studying • Astigmatism accompanies myopia in ~ 25% of cases* Half of the global population is 6000 60% expected to have 5000 50% myopia by 2050** 4000 40% 30
Slide 5: The Existing Myopia Market is Millions of Eyes
The Existing Myopia Market is Millions of Eyes 740K 1.1M 210K 300K Opportunity 960K 910K India W.Europe 6M frequent replacement contact lens wearers drop out each year in the U.S. alone** Latin America USA Annual Global Spend** China R.O.W. $6 B $16 B $48 B 4.2 M Annual Global Refractive Procedures*
Slide 6: STAAR's TAM is Tens of Millions of Eyes
STAAR’s TAM is Tens of Millions of Eyes Global Prevalence STAAR Adjustments to Global Prevalence Epidemiological Data 1.9 B 1.7 B STAAR’s TAM* Myopes Presbyopes Distribution of Uncorrected Refractive Error Myopia Presbyopia Distance Vision Willingness to Undergo Refractive Near Vision 70 M (Nearsigh
Slide 7: STAAR's ICL Technology
An Evolution in Visual Freedom STAAR’S ICL TECHNOLOGY 07
Slide 8: EVO ICL Technology
EVO ICL Technology A single-piece foldable phakic intraocular lens (IOL) implanted within the posterior chamber of the eye directly behind the iris and in front of the natural crystalline lens, designed to correct refractive error… Natural Iris EVO ICL™ Crystalline Lens 08
Slide 9: Why EVO ICL? Patients and Surgeons Tell Us…
Why EVO ICL? Patients and Surgeons Tell Us… Bio-Compatible Quiet in Eco-Friendly No Dry Eye the Eye Syndrome Additive Collamer Quality Removable Material of Vision UV Excellent Upgradeable No Capital Protection Night Vision Equipment Investment 09
Slide 10: 2 Million+ Happy ICL Patients
Happy ICL Patients 2 Million+ ICLs Sold Globally * Packer, The Implantable Collamer Lens with a central port: review of the literature, Clinical Ophthalmology, 2018. 10
Slide 11: ICL Around the World
ICL AROUND THE WORLD 11
Slide 12: China – Increasing Share of #1 Global Market
China – Increasing Share of #1 Global Market EVO ICL share of the refractive market grew from approximately 2% in 2015 to milestone 20%+ in 2020… China: the first large Patient roadshows, in- market to adopt our person and virtually on model of strategic social media such as cooperation in 2016 WeCh
Slide 13: United States – Executing Playbook as we Launch EVO ICL
United States – Executing Playbook as we Launch EVO ICL in #2 Global Market Strategic Imperative Drive U.S. growth by successfully commercializing our market-transforming EVO ICL family of myopia lenses following FDA Approval on March 25, 2022 Artist’s Rendition Build upon foundational work since 20
Slide 14: Europe – Accelerating a Growth Renaissance
Europe – Accelerating a Growth Renaissance Driving growth via Surgeon Support and Strategic Sales & Marketing Investments Increasing distributor-to-hybrid market conversions with goal of accelerating growth, e.g. France, Italy and Benelux Making sales & marketing investments that include broadening
Slide 15: We're Just Getting Started…
We’re Just Getting Started… ~ 9% ICL share of global market* * Approximate ICL unit share of 2021 global refractive myopia market. 15
Slide 16: STAAR's Track Record of Strong Financial Performance
STAAR’s Track Record of Strong Financial Performance 16
Slide 17: ICL Unit Growth Significantly Exceeds Refractive Industry
ICL Unit Growth Significantly Exceeds Refractive Industry Select Markets, ICL Unit Growth Y/Y Global Refractive Industry Procedures* Global ICL Units 2021 2020 2019 45% 48% China 16% 48% 60% 33% Japan 59% 65% 34% 17% S. Korea 17% 11% 30% 4% 40% Other APAC Markets 40% 22% 32% Germany 12% 18% (21%) 36
Slide 18: ICL Unit Growth Drives Industry Leading Net Sales Growth
ICL Unit Growth Drives… Industry Leading Net Sales Growth ~ +25% CAGR 41% 37% 28% 21% 10% 9% 2017 2018 2019 2020 2021 2022 Outlook $90.6 Million $124.0 Million $150.2 Million $163.5 Million* $230.5 Million $295 Million +10% Growth +37% Growth +21% Growth +9% Growth +41% Growth +28% Growth 2017 2018
Slide 19: STAAR's Expanding Margins, EPS and Cash
STAAR’s Expanding Margins, EPS and Cash Operating Margin GAAP EPS* Cash from Operations $0.50 $ Millions $44.0 14.5% $0.30 7.9% $25.8 5.3% 4.1% $0.12 $21.0 $0.11 $12.8 (4.0%) $(0.05) $2.9 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 Cash on Balance Sheet - Quarter-End $
Slide 20: Recent Success and Strong Outlook
Recent Success and Strong Outlook First Quarter 2022 Results Reported May 4, 2022 Net Sales Growth Global ICL Unit 25% Y/Y to $63.2 Million 29% Growth Y/Y Fiscal Year 2022 Outlook Focus remains on advancing our strong growth trajectory for EVO ICL lenses STAAR is one of just a few U.S. publicly Driv
Slide 21: Envision a Life Without Hesitation
Envision a Life Without Hesitation We invite you to visit STAAR’s investor website www.staar.com for clinical papers, examples of global consumer marketing www.discoverevo.com and much more at investors.staar.com
STAAR Surgical Company — Investor Presentation (June 2022) on 6ix